A Multicenter, Randomized, Open-Label, Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Latest Information Update: 17 Mar 2026
At a glance
- Drugs Adebrelimab (Primary) ; Risvutatug rezetecan (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 17 Mar 2026 New trial record